Marcel Seungsu Woo

Marcel Seungsu Woo

Auto-generated profile, based on publicly available information

Marcel Seungsu Woo

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Brain Communications
Verified
Journal Article
Open access
PDF file
MWMarcel S Woo
Marcel S Woo
JMJakob Malsy
Jakob Malsy
JPJana Pöttgen
Jana Pöttgen
SZSusan Seddiq Zai
Susan Seddiq Zai
FUFriederike Ufer
Friederike Ufer
MFManuel A Friese
Manuel A Friese
Neuropsychiatric complications associated with coronavirus disease 2019 caused by the Coronavirus SARS-CoV-2 (COVID-19) are increasingly appreciated. While most studies have focussed on severely affected individuals during acute infection, it remains unclear whether mild COVID-19 results in neurocognitive deficits in young patients. Here, we established a screening approach to detect cognitive deficiencies in post-COVID-19 patients. In this cross-sectional study, we recruited 18 mostly young patients 20–105 days (median, 85 days) after recovery from mild to moderate disease who visited our outpatient clinic for post-COVID-19 care. Notably, 14 (78%) patients reported sustained mild cognitive deficits and performed worse in the Modified Telephone Interview for Cognitive Status screening test for mild cognitive impairment compared to 10 age-matched healthy controls. While short-term memory, attention and concentration were particularly affected by COVID-19, screening results did not correlate with hospitalization, treatment, viremia or acute inflammation. Additionally, Modified Telephone Interview for Cognitive Status scores did not correlate with depressed mood or fatigue. In two severely affected patients, we excluded structural or other inflammatory causes by magnetic resonance imaging, serum and cerebrospinal fluid analyses. Together, our results demonstrate that sustained sub-clinical cognitive impairments might be a common complication after recovery from COVID-19 in young adults, regardless of clinical course that were unmasked by our diagnostic approach.

24 May 2024 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
MWMarcel S. Woo
Marcel S. Woo
JEJan Broder Engler
Jan Broder Engler
MFManuel A. Friese
Manuel A. Friese

14 June 2024 in Cell
Verified
Journal Article
Open access
MWMarcel S. Woo
Marcel S. Woo
CMChristina Mayer
Christina Mayer
LBLars Binkle-Ladisch
Lars Binkle-Ladisch
JSJana K. Sonner
Jana K. Sonner
RCRosenkranz Sina Cathérine
Rosenkranz Sina Cathérine
MFManuel A. Friese
Manuel A. Friese
Inflammation-induced neurodegeneration is a defining feature of multiple sclerosis (MS), yet the underlying mechanisms remain unclear. By dissecting the neuronal inflammatory stress response, we discovered that neurons in MS and its mouse model induce the stimulator of interferon genes (STING). However, activation of neuronal STING requires its detachment from the stromal interaction molecule 1 (STIM1), a process triggered by glutamate excitotoxicity. This detachment initiates non-canonical STING signaling, which leads to autophagic degradation of glutathione peroxidase 4 (GPX4), essential for neuronal redox homeostasis and thereby inducing ferroptosis. Both genetic and pharmacological interventions that target STING in neurons protect against inflammation-induced neurodegeneration. Our findings position STING as a central regulator of the detrimental neuronal inflammatory stress response, integrating inflammation with glutamate signaling to cause neuronal cell death, and present it as a tractable target for treating neurodegeneration in MS.

12 November 2024 in Nature Aging
Verified
Journal Article
Open access
PDF file
JTJoseph Therriault
Joseph Therriault
SJShorena Janelidze
Shorena Janelidze
ABAndréa Lessa Benedet
Andréa Lessa Benedet
NANicholas J. Ashton
Nicholas J. Ashton
JMJavier Arranz Martínez
Javier Arranz Martínez
PRPedro Rosa-Neto
Pedro Rosa-Neto
Recently approved anti-amyloid immunotherapies for Alzheimer’s disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.

22 April 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
BSBenjamin Schattling
Benjamin Schattling
JEJan Broder Engler
Jan Broder Engler
CVConstantin Volkmann
Constantin Volkmann
NRNicola Rothammer
Nicola Rothammer
MWMarcel S. Woo
Marcel S. Woo
MFManuel A. Friese
Manuel A. Friese

15 July 2023 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
MWMarcel S. Woo
Marcel S. Woo
MSMohsin Shafiq
Mohsin Shafiq
AFAntonia Fitzek
Antonia Fitzek
MDMatthias Dottermusch
Matthias Dottermusch
HAHermann Altmeppen
Hermann Altmeppen
MGMarkus Glatzel
Markus Glatzel
Dysautonomia has substantially impacted acute COVID-19 severity as well as symptom burden after recovery from COVID-19 (long COVID), yet the underlying causes remain unknown. Here, we hypothesized that vagus nerves are affected in COVID-19 which might contribute to autonomic dysfunction. We performed a histopathological characterization of postmortem vagus nerves from COVID-19 patients and controls, and detected SARS-CoV-2 RNA together with inflammatory cell infiltration composed primarily of monocytes. Furthermore, we performed RNA sequencing which revealed a strong inflammatory response of neurons, endothelial cells, and Schwann cells which correlated with SARS-CoV-2 RNA load. Lastly, we screened a clinical cohort of 323 patients to detect a clinical phenotype of vagus nerve affection and found a decreased respiratory rate in non-survivors of critical COVID-19. Our data suggest that SARS-CoV-2 induces vagus nerve inflammation followed by autonomic dysfunction which contributes to critical disease courses and might contribute to dysautonomia observed in long COVID.